Your browser doesn't support javascript.
loading
Molecular pathology and clinical treatment of independent HPV primary serous carcinoma of the uterine cervix (USCC): A case report.
Niu, Lina; Ruan, Fangying; Yang, Qisheng; Xia, Chaoran; Xu, Tao; Dong, Fei; Zhang, Lizhen; Guo, Sheng; Lv, Weiqin; Wang, Junxia; Shang, Yun.
Afiliação
  • Niu L; Department of Gynecology Yuncheng Central Hospital, Shanxi Province Yuncheng China.
  • Ruan F; Zhejiang Shaoxing Topgen Biomedical Technology Co., Ltd Shanghai China.
  • Yang Q; Zhejiang Shaoxing Topgen Biomedical Technology Co., Ltd Shanghai China.
  • Xia C; Zhejiang Shaoxing Topgen Biomedical Technology Co., Ltd Shanghai China.
  • Xu T; Department of Pathology Yuncheng Central Hospital, Shanxi Province Yuncheng China.
  • Dong F; Department of Medical Imaging Yuncheng Central Hospital, Shanxi Province Yuncheng China.
  • Zhang L; Department of Gynecology Yuncheng Central Hospital, Shanxi Province Yuncheng China.
  • Guo S; Department of Gynecology Yuncheng Central Hospital, Shanxi Province Yuncheng China.
  • Lv W; Department of Gynecology Yuncheng Central Hospital, Shanxi Province Yuncheng China.
  • Wang J; Department of Gynecology Yuncheng Central Hospital, Shanxi Province Yuncheng China.
  • Shang Y; Department of Gynecology Yuncheng Central Hospital, Shanxi Province Yuncheng China.
Clin Case Rep ; 11(9): e7833, 2023 Sep.
Article em En | MEDLINE | ID: mdl-37663823
ABSTRACT
On October 23, 2020, a 69-year-old Chinese female patient was admitted to Yuncheng Hospital due to a history of postmenopausal bleeding and lower abdominal pain for 5 months. The HPV test and pathology results indicated the presence of independent HPV in primary serous carcinoma of the uterine cervix. The genetic testing identified variants of uncertain significance (PAX8 p.Tyr 410 Ter and TP53 p.Asn 247 Ile), microsatellite instability stable (MSI-S), tumor mutational burden (TMB) 7.33Muts/Mb, and an elevated tumor neoantigen burden. Before undergoing radical hysterectomy treatment, the patient exhibited a positive response to three cycles of intravenous docetaxel (100 mg/3 h) and carboplatin (450 mg/1 h). Following the surgery, she received an additional three cycles of docetaxel (100 mg/3 h) and carboplatin (500 mg/1 h), accompanied by 25 cycles of radiation therapy (DT 46Gy/2Gy/23f). Concurrently, cisplatin (450 mg/1 h) was administered. As of now, the patient has achieved 20 months of disease-free survival.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Clin Case Rep Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Clin Case Rep Ano de publicação: 2023 Tipo de documento: Article